461 related articles for article (PubMed ID: 34706850)
1. Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
Hu J; Aprikian AG; Vanhuyse M; Dragomir A
Clin Genitourin Cancer; 2022 Feb; 20(1):17-24. PubMed ID: 34706850
[TBL] [Abstract][Full Text] [Related]
2. Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
Liu JM; Lin CC; Chen MF; Liu KL; Lin CF; Chen TH; Wu CT
Prostate; 2021 Feb; 81(3):194-201. PubMed ID: 33393676
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data.
Conover MM; Weaver J; Fan B; Leitz G; Richarz U; Li Q; Gifkins D
Prostate; 2023 May; 83(7):729-739. PubMed ID: 36879362
[TBL] [Abstract][Full Text] [Related]
4. Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.
Pilon D; Behl AS; Ellis LA; Emond B; Lefebvre P; Dawson NA
J Manag Care Spec Pharm; 2017 Feb; 23(2):225-235. PubMed ID: 28125362
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide.
Scailteux LM; Vincendeau S; Gravis G; Mathieu R; Balusson F; Kerbrat S; Oger E
Clin Genitourin Cancer; 2023 Oct; 21(5):e362-e369. PubMed ID: 37188606
[TBL] [Abstract][Full Text] [Related]
6. Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec.
Hu J; Aprikian AG; Saleh RR; Dragomir A
Curr Oncol; 2022 Nov; 29(11):8626-8637. PubMed ID: 36421333
[TBL] [Abstract][Full Text] [Related]
7. Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014-2018 French Population Study (the SPEAR Cohort).
Scailteux LM; Campillo-Gimenez B; Kerbrat S; Despas F; Mathieu R; Vincendeau S; Balusson F; Happe A; Nowak E; Oger E
Am J Epidemiol; 2021 Feb; 190(3):413-422. PubMed ID: 32944756
[TBL] [Abstract][Full Text] [Related]
8. Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan.
Miyake H; Hara T; Terakawa T; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Apr; 15(2):313-319. PubMed ID: 27424256
[TBL] [Abstract][Full Text] [Related]
9. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
Kwon DH; Paciorek A; Zhang L; Borno HT; Bucknor M; Small EJ; Aggarwal RR
Urol Oncol; 2022 Aug; 40(8):379.e17-379.e24. PubMed ID: 35750560
[TBL] [Abstract][Full Text] [Related]
10. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
[TBL] [Abstract][Full Text] [Related]
12. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Kuppen MCP; Westgeest HM; van den Eertwegh AJM; van Moorselaar RJA; van Oort IM; Coenen JLLM; van den Bergh ACMF; Mehra N; Somford DM; Bergman AM; Ten Bokkel Huinink D; Fossion L; Geenen MM; Hendriks MP; van de Luijtgaarden ACM; Polee MB; Weijl NI; van de Wouw AJ; de Wit R; Uyl-de Groot CA; Gerritsen WR
Eur Urol Oncol; 2021 Aug; 4(4):618-627. PubMed ID: 31601523
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
14. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide.
Baser O; Samayoa G; Dwivedi A; AlSaleh S; Cigdem B; Kizilkaya E
Acta Oncol; 2024 Apr; 63():137-146. PubMed ID: 38591349
[TBL] [Abstract][Full Text] [Related]
15. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Chen HK; Su PJ; Wang YL; Chang KC; Su YL; Chang PH; Kuan FC; Hsieh CH; Kuo YC; Sheng TW; Chang CF; Yu SM; Huang WK; Lin YC; Tsan DL; Yu KJ; Lin PH; Chen HY; Chang YH; Pang ST; Chuang CK; Lai EC
Int J Cancer; 2023 Mar; 152(6):1191-1201. PubMed ID: 36346116
[TBL] [Abstract][Full Text] [Related]
16. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
[TBL] [Abstract][Full Text] [Related]
17. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis.
Mori K; Miura N; Mostafaei H; Quhal F; Sari Motlagh R; Pradere B; Kimura S; Kimura T; Egawa S; Briganti A; Karakiewicz PI; Shariat SF
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):539-548. PubMed ID: 32152435
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
19. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
20. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]